The structure of fibrinogen, with its diverse functional groups, allows for various modifications. For instance, PEGylation involves introducing polyethylene glycol (PEG) chains to fibrinogen, imparting several advantages to the resulting biomaterials. PEGylation enhances the stability and solubility of fibrinogen, reduces its immunogenicity, and prolongs its circulation time, thereby improving its overall biocompatibility. Furthermore, PEGylation can facilitate the adjustment of fibrinogen's degradation rate by proteolytic enzymes occurring in body fluids and tissues. This capability enables the design of biocompatible carriers with the potential for controlled release kinetics of active compounds and tailored degradation profiles. . The introduction of PEGylated fibrinogen into the hybrid structure imparts enhanced biodegradation of biomaterials making them more suitable for a broad spectrum of medical applications .